Avoiding backward steps in COPD: looking again at roflumilast.
نویسنده
چکیده
score, air-flow limitation and exercise tolerance) Index: a new composite score for the stratification of severity in chronic obstructive pulmonary disease. Postgrad Med J 2007; 83: 492–497. 13 Cardoso F, Tufanin AT, Colucci M, et al. Replacement of the 6-min walk test with maximal oxygen consumption in the BODE Index applied to patients with COPD: an equivalency study. Chest 2007; 132: 477–482. 14 Schembri S, Anderson W, Morant S, et al. A predictive model of hospitalisation and death from chronic obstructive pulmonary disease. Respir Med 2009; 103: 1461–1467. 15 Esteban C, Arostegui I, Moraza J, et al. Development of a decision tree to assess the severity and prognosis of stable COPD. Eur Respir J 2011; 38: 1294–1300. 16 Altman DG, Vergouwe Y, Royston P, et al. Prognosis and prognostic research: validating a prognostic model. BMJ 2009; 338: b605. 17 Moons KG, Altman DG, Vergouwe Y, et al. Prognosis and prognostic research: application and impact of prognostic models in clinical practice. BMJ 2009; 338: b606.
منابع مشابه
The safety and effectiveness of the current treatment regimen with or without roflumilast in advanced COPD patients: A systematic review and meta-analysis of randomized controlled trials
Background: Chronic obstructive pulmonary disease (COPD) is a chronic respiratory disease, which reduces the lung function and causes respiratory symptoms over time, and it is primarily associated with shortness of breath, cough and sputum production. Roflumilast, which is a long-acting selective inhibitor, reduces the anti-inflammatory effect of the main symptoms of COPD. The aim of ...
متن کاملImpact of roflumilast on exacerbations of COPD, health care utilization, and costs in a predominantly elderly Medicare Advantage population
BACKGROUND Chronic obstructive pulmonary disease (COPD) exacerbations are associated with declining lung function and health-related quality of life, and increased hospitalization and mortality. Clinical trials often poorly represent the elderly and thus have only partial applicability to their clinical care. OBJECTIVE To compare exacerbations, COPD-related health care utilization (HCU), and ...
متن کاملVulnerable COPD patients with comorbidities: the role of roflumilast
Roflumilast is a selective phosphodiesterase-4 (PDE-4) inhibitor that was approved by the US Food and Drug Administration in February 2011 for the management of chronic obstructive pulmonary disease (COPD). Literature was retrieved through PubMed using the terms "roflumilast" and "COPD". Reference citations from publications identified were also reviewed. All articles published in English using...
متن کاملRoflumilast: a review of its use in the treatment of COPD
COPD is a progressive condition involving chronic inflammation and parenchymal destruction with resulting airflow limitation. COPD is associated with worsening airflow limitation over time and increased frequency of COPD exacerbations, leading to increased mortality and morbidity. The effects of COPD extend beyond the lungs, as multiple comorbidities may occur with COPD, including cardiovascula...
متن کاملA longitudinal, retrospective cohort study on the impact of roflumilast on exacerbations and economic burden among chronic obstructive pulmonary disease patients in the real world
BACKGROUND Roflumilast is approved in the United States to reduce the risk of COPD exacerbations in patients with severe COPD. Exacerbation rates, health care resource utilization (HCRU), and costs were compared between roflumilast patients and those receiving other COPD maintenance drugs. METHODS LifeLink™ Health Plan Claims Database was used to identify patients diagnosed with COPD who init...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- The European respiratory journal
دوره 39 1 شماره
صفحات -
تاریخ انتشار 2012